• Prime Medicine dosed the first patient in a global Phase 1/2 trial of PM577a for H1069Q-mutated Wilson disease.
• The first-in-human study aims to assess safety and early signs of benefit from a one-time gene-editing treatment.
• Initial clinical data are expected in 2027, with results to be presented in the future.
• The FDA granted Rare Pediatric Disease designation to PM577, supporting the program’s regulatory strategy in a childhood-onset condition.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050800PRIMZONEFULLFEED9839217) on October 05, 2026, and is solely responsible for the information contained therein.